Status:
UNKNOWN
Efficacy of Continuous Terlipressin Therapy After Endoscopic Variceal Ligation
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Variceal Hemorrhage
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Upper gastrointestinal (UGI) bleed of variceal origin is a common medical emergency. Prompt endoscopic variceal ligation (EVL) is therapeutic as well as diagnostic. Terlipressin, a vasopressin analog ...
Eligibility Criteria
Inclusion
- Irrespective of gender
- age ≥ 18 years
- all the patients with endoscopy proven acute VH with successful EVL done
Exclusion
- Patients not receiving pre-EVL Terlipressin therapy
- not achieving haemostasis during EVL
- EVL done beyond 48 hours of admission because of hemodynamic instability or encephalopathy
- Patients with chronic kidney disease
- Patients with pregnancy
- Patients who are receiving blood thinners like anti-platelets, anti-coagulation agents within 4 weeks of presentation
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT06027970
Start Date
September 1 2023
End Date
December 1 2024
Last Update
September 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, Post Graduate Institute of Medical Education and Research,
Chandigarh, India, 160012